ALCAM - Novel multiple sclerosis locus interfering with HLA-DRB1*1501

19Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Activated leukocyte cell adhesion molecule (ALCAM) is a molecule involved in leukocyte migration across the blood-brain barrier which is a key stage in multiple sclerosis (MS) pathogenesis. The present study is the first to report evidence of the association of rs6437585 ALCAM polymorphism with risk and progression of MS. Our investigation revealed that rs6437585CT individuals had higher risk of MS (OR = 2.34; 95%CI = 1.22-4.51; P= 0.011) and over 2. years earlier age of onset (95%CI = 0.16-4.41, P= 0.036).Moreover, we demonstrated that two ALCAM polymorphisms, rs11559013 and rs34926152, although not associated with MS itself, modify HLA-DRB1*1501 effect. Results obtained from logistic regression analysis showed five-fold lower risk for MS for both rs11559013GA/. HLA-DRB1*1501+ and rs34926152GT/. HLA-DRB1*1501+ individuals. This observations may suggest protective role against MS for both rs11559013GA and rs34926152GT genotypes in HLA-DRB1*1501 positive individuals. © 2013 Elsevier B.V.

Cite

CITATION STYLE

APA

Wagner, M., Wiśniewski, A., Bilińska, M., Pokryszko-Dragan, A., Nowak, I., Kuśnierczyk, P., & Jasek, M. (2013). ALCAM - Novel multiple sclerosis locus interfering with HLA-DRB1*1501. Journal of Neuroimmunology, 258(1–2), 71–76. https://doi.org/10.1016/j.jneuroim.2013.02.015

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free